The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe.

dc.contributor.author	Skurtveit, Svetlana
dc.contributor.author	Bramness, Jørgen
dc.contributor.author	Buajordet, Ingebjørg
dc.date.accessioned	2011-04-13T09:32:56Z
dc.date.available	2011-04-13T09:32:56Z
dc.date.issued	2008
dc.identifier.citation	Norsk Epidemiologi 18(2008) nr. 2 s. 167-172	en
dc.identifier.cristinID	FRIDAID 336296
dc.identifier.issn	0803-2491
dc.identifier.uri	https://hdl.handle.net/10037/3182
dc.identifier.urn	URN:NBN:no-uit_munin_2913
dc.language.iso	eng	en
dc.publisher	Norsk forening for epidemiologi	en
dc.rights.accessRights	openAccess
dc.subject	VDP::Medical disciplines: 700::Health sciences: 800::Community pharmacy: 812	en
dc.subject	VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsfarmasi: 812	en
dc.title	The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe.	en
dc.type	Journal article	en
dc.type	Tidsskriftartikkel	en
dc.type	Peer reviewed	en